Most individuals with mood disorders experience psychiatric and/or medical comorbidity. Available treatment guidelines for major depressive disorder (MDD) and bipolar disorder (BD) have focused on treating mood disorders in the absence of comorbidity. Treating comorbid conditions in patients with mood disorders requires sufficient decision support to inform appropriate treatment.
Methods
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force sought to prepare evidence- and consensus-based recommendations on treating comorbid conditions in patients with MDD and BD by conducting a systematic and qualitative review of extant data. The relative paucity of studies in this area often required a consensus-based approach to selecting and sequencing treatments.
Results
Several principles emerge when managing comorbidity. They include, but are not limited to: establishing the diagnosis, risk assessment, establishing the appropriate setting for treatment, chronic disease management, concurrent or sequential treatment, and measurement-based care.
Conclusions
Efficacy, effectiveness, and comparative effectiveness research should emphasize treatment and management of conditions comorbid with mood disorders. Clinicians are encouraged to screen and systematically monitor for comorbid conditions in all individuals with mood disorders. The common comorbidity in mood disorders raises fundamental questions about overlapping and discrete pathoetiology.
SchafferA, McIntoshD, GoldsteinBI, . The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24:6–22.
2.
BondDJ, HadjipavlouG, LamRW, . The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24:23–37.
3.
BeaulieuS, SauryS, SareenJ, . The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry. 2012;24:38–55.
4.
RosenbluthM, MacQueenG, McIntyreRS, . The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Ann Clin Psychiatry. 2012;24:56–68.
5.
McIntyreRS, AlsuwaidanM, GoldsteinBI, . The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24:69–81.
6.
RamasubbuR, BeaulieuS, TaylorVH, . The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry. 2012;24:82–90.
7.
RamasubbuR, TaylorVH, SamaanZ, . The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012;24:91–109.
8.
YathamLN, KennedySH, SchafferA, . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–255.
9.
KennedySH, LamRW, ParikhSV, . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord. 2009;117:S1–S2.
10.
McElroySL, FryeMA, HellemannG, . Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord. 2011;128:191–198.
11.
HarveyAG, SchmidtDA, ScarnàA, . Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry. 2005;162:50–57.
12.
Martín-MerinoE, RuigómezA, JohanssonS, . Study of a cohort of patients newly diagnosed with depression in general practice: prevalence, incidence, comorbidity, and treatment patterns. Prim Care Companion J Clin Psychiatry. 2010;12:PCC.08m00764.
13.
KesslerRC, MerikangasKR, Wang PrevalencePS., comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol. 2007;3:137–158.
14.
MerglR, SeidscheckI, AllgaierAK, . Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. Depress Anxiety. 2007;24:185–195.
15.
McIntyreRS, KeckPEJr.Comorbidity in bipolar disorder: clinical and research opportunities. Bipolar Disord. 2006;8:645–647.
16.
McElroySL, AltshulerLL, SuppesT, . Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158:420–426.
17.
McElroySL, PopeHGJr, KeckPEJr, . Are impulse-control disorders related to bipolar disorder?Compr Psychiatry. 1996;37:229–240.
18.
KesslerRC, BerglundP, DemlerO, . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.
19.
KesslerRC, RubinowDR, HolmesC, . The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med. 1997;27:1079–1089.
20.
StinsonFS, GrantBF, DawsonDA, . Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2005;80:105–116.
21.
SimonNM, OttoMW, WisniewskiSR, . Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222–2229.
22.
AngstJ, CuiL, SwendsenJ, . Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010;167:1194–1201.
23.
JuddLL, SchettlerPJ, AkiskalH, . Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes. J Affect Disord. 2012;138:440–448.
24.
MerikangasKR, AkiskalHS, AngstJ, . Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–552.
25.
MerikangasKR, KalaydjianA.Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys. Curr Opin Psychiatry. 2007;20:353–358.
26.
FeinsteinAR, WalterSD, HorwitzRI.An analysis of Berkson's bias in case-control studies. J Chronic Dis. 1986;39:495–504.
27.
TrivediMH, RushAJ, WisniewskiSR, . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
28.
KilbourneAM, CorneliusJR, HanX, . Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–373.
29.
MerikangasKR, ZhangH, AvenevoliS, . Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry. 2003;60:993–1000.
30.
ThompsonWK, KupferDJ, FagioliniA, . Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry. 2006;67:783–788.
31.
McIntyreRS, KennedySH, SoczynskaJK, . Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. Prim Care Companion J Clin Psychiatry. 2010;12:pii: PCC.09m00861.
32.
SimonGE, UnützerJ.Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999;50:1303–1308.
33.
KrishnanV, NestlerEJ.Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry. 2010;167:1305–1320.
34.
VolkowND, WangGJ, TelangF, . Inverse association between BMI and prefrontal metabolic activity in healthy adults. Obesity (Silver Spring). 2009;17:60–65.
35.
VolkowND, WiseRA.How can drug addiction help us understand obesity? Nat Neurosci. 2005;8:555–560.
36.
VolkowN, LiTK.The neuroscience of addiction. Nat Neurosci. 2005;8:1429–1430.
37.
McIntyreRS, McElroySL, KonarskiJZ, . Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68:1352–1357.
38.
MacKinnonDF, ZandiPP, CooperJ, . Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry. 2002;159:30–35.
39.
MacKinnonDF, XuJ, McMahonFJ, . Bipolar disorder and panic disorder in families: an analysis of chromosome 18 data. Am J Psychiatry. 1998;155:829–831.
McIntyreRS.Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry. 2009;70:e17.
42.
RedelmeierDA, TanSH, BoothGL.The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516–1520.
43.
KupferDJ.The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528–2530.
44.
McIntyreRS, SoczynskaJK, BeyerJL, . Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. 2007;20:406–416.
45.
JablenskyA, KendellRE.Criteria for assessing a classification in psychiatry. In: MaiM, GaebelW, López-IborJJ, ., eds. Psychiatric diagnosis and classification.New York, NY: John Wiley & Sons, Ltd.; 2002:1–24.
46.
CostelloEJ, MustilloS, ErkanliA, . Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003;60:837–844.
47.
FerdinandRF, DielemanG, OrmelJ, . Homotypic versus heterotypic continuity of anxiety symptoms in young adolescents: evidence for distinctions between DSM-IV subtypes. J Abnorm Child Psychol. 2007;35:325–333.
48.
StrakowskiSM, DelBelloMP, FleckDE, . Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania. Arch Gen Psychiatry. 2005;62:851–858.
49.
StrakowskiSM, DelBelloMP, FleckDE, . Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64:57–64.
50.
MitchellAJ, VazeA, RaoS.Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374:609–619.
51.
HirschfeldRM, CalabreseJR, WeissmanMM, . Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53–59.
52.
NortonPJ, TempleSR, PettitJW.Suicidal ideation and anxiety disorders: elevated risk or artifact of comorbid depression?J Behav Ther Exp Psychiatry.2008;39:515–525.
53.
FryeMA, SalloumIM.Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006;8:677–685.
54.
DilsaverSC, AkiskalHS, AkiskalKK, . Doseresponse relationship between number of comorbid anxiety disorders in adolescent bipolar/unipolar disorders, and psychosis, suicidality, substance abuse and familiality. J Affect Disord. 2006;96:249–258.
55.
GoldbergJF, SingerTM, GarnoJL.Suicidality and substance abuse in affective disorders. J Clin Psychiatry. 2001;62:35–43.
56.
WallerSJ, LyonsJS, Costantini-FerrandoMF.Impact of comorbid affective and alcohol use disorders on suicidal ideation and attempts. J Clin Psychol. 1999;55:585–595.
57.
KatonWJ.Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54:216–226.
58.
Von KorffM, KatonW, UnützerJ, . Improving depression care: barriers, solutions, and research needs. J Fam Pract. 2001;50:E1.
